Kalkine has a fully transformed New Avatar.

Last update at 2026-03-10T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
How A Mixed Sector Backdrop Is Shaping The Evolving Story For Alcidion Group (ASX:ALC)
Wed 25 Feb 26, 04:10 PMASX Penny Stocks To Watch With Market Caps Larger Than A$100M
Sun 11 Jan 26, 08:02 PMWhy The Narrative Around Alcidion Group ASX ALC Is Shifting With New Fair Value Signals
Sun 11 Jan 26, 09:12 AM3 Promising Undervalued Small Caps With Insider Action In Global Markets
Tue 23 Sep 25, 09:39 AMASX Penny Stocks Spotlight: Alcidion Group And 2 Other Noteworthy Picks
Fri 19 Sep 25, 03:05 AMDP World subsidiary to acquire 51% stake in NovaAlgoma cement assets
Thu 03 Jul 25, 01:57 PMAlcon Q1 Earnings Miss Estimates, Stock Down, 2025 EPS View Lowered
Wed 14 May 25, 12:49 PMAlcon (ALC) Reports Q1 Earnings: What Key Metrics Have to Say
Tue 13 May 25, 10:00 PMApril CPI, On Holding earnings, NFIB optimism: What to Watch
Mon 12 May 25, 11:00 PM| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | 1256.00M | 832.00M | 463.00M | 418.00M | -635.00000M |
| Minority interest | - | - | - | - | - |
| Net income | 1018.00M | 974.00M | 335.00M | 376.00M | -531.00000M |
| Selling general administrative | 3250.00M | 3209.00M | 3068.00M | 3057.00M | 2694.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 5512.00M | 5247.00M | 4748.00M | 4652.00M | 2940.00M |
| Reconciled depreciation | 1228.00M | 1221.00M | 1123.00M | 1219.00M | 1626.00M |
| Ebit | 1448.00M | 1021.00M | 616.59M | 539.14M | -611.36711M |
| Ebitda | 2676.00M | 2242.00M | 1776.43M | 1760.74M | 1112.00M |
| Depreciation and amortization | 1228.00M | 1221.00M | 1159.84M | 1221.59M | 1723.37M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 1413.00M | 1039.00M | 672.00M | 580.00M | -482.00000M |
| Other operating expenses | 8498.00M | 8416.00M | 8045.00M | 7711.00M | 7315.00M |
| Interest expense | 192.00M | 189.00M | 134.00M | 120.00M | 124.00M |
| Tax provision | 238.00M | -142.00000M | 128.00M | 42.00M | -104.00000M |
| Interest income | 84.00M | 45.00M | 16.00M | 146.00M | 6.00M |
| Net interest income | -120.00000M | -155.00000M | -146.00000M | -162.00000M | -131.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 238.00M | -142.00000M | 128.00M | 42.00M | -104.00000M |
| Total revenue | 9911.00M | 9455.00M | 8717.00M | 8291.00M | 6833.00M |
| Total operating expenses | 4099.00M | 4208.00M | 4076.00M | 4072.00M | 3422.00M |
| Cost of revenue | 4399.00M | 4208.00M | 3969.00M | 3639.00M | 3893.00M |
| Total other income expense net | -157.00000M | -207.00000M | -209.00000M | -162.00000M | -153.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 1018.00M | 974.00M | 335.00M | 376.00M | -531.00000M |
| Net income applicable to common shares | - | - | 335.00M | 376.00M | -531.00000M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 30347.00M | 29614.00M | 29209.00M | 27999.00M | 27600.00M |
| Intangible assets | 8587.00M | 9060.00M | 9689.00M | 8765.00M | 9097.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 129.00M | 241.96M | 418.00M | 95.00M | 404.00M |
| Total liab | 8794.00M | 8990.00M | 9532.00M | 8743.00M | 8778.00M |
| Total stockholder equity | 21553.00M | 20617.02M | 19677.00M | 19256.00M | 18822.00M |
| Deferred long term liab | - | - | - | 557.00M | 727.00M |
| Other current liab | 1100.16M | 1338.20M | 1664.00M | 1287.00M | 1040.00M |
| Common stock | 20.00M | 19.99M | 20.00M | 20.00M | 20.00M |
| Capital stock | 20.00M | 20.00M | 20.00M | 20.00M | 20.00M |
| Retained earnings | - | - | - | 19356.00M | 18899.00M |
| Other liab | - | - | 1850.00M | 1966.00M | 2256.00M |
| Good will | 8946.00M | 8926.00M | 8970.00M | 8905.00M | 8905.00M |
| Other assets | - | -10.02816M | 833.00M | 1365.00M | 1515.00M |
| Cash | 1829.00M | 1094.00M | 980.00M | 1575.00M | 1557.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 2278.00M | 2479.16M | 2782.00M | 2472.00M | 2258.00M |
| Current deferred revenue | 72.84M | -0.83980M | 89.00M | 108.00M | 110.00M |
| Net debt | 3307.00M | 4041.00M | 4088.00M | 2904.00M | 2939.00M |
| Short term debt | 169.00M | 216.00M | 168.00M | 174.00M | 232.00M |
| Short long term debt | 101.00M | 135.00M | 97.00M | 107.00M | 162.00M |
| Short long term debt total | 5136.00M | 5135.00M | 5068.00M | 4479.00M | 4496.00M |
| Other stockholder equity | - | - | 19657.00M | 19236.00M | 18802.00M |
| Property plant equipment | - | - | 4416.00M | 4083.00M | 3783.00M |
| Total current assets | 6309.00M | 5647.00M | 5193.00M | 5386.00M | 4987.00M |
| Long term investments | 751.00M | 319.00M | 108.00M | 52.00M | 40.00M |
| Net tangible assets | - | - | 1018.00M | 2143.00M | 1547.00M |
| Short term investments | 1.00M | 7.00M | -179.00000M | 3.00M | 12.00M |
| Net receivables | 2082.00M | 1981.33M | 1686.00M | 1814.00M | 1382.00M |
| Long term debt | 4538.00M | 4594.00M | 4541.00M | 3966.00M | 3949.00M |
| Inventory | 2268.00M | 2322.00M | 2109.00M | 1899.00M | 1644.00M |
| Accounts payable | 773.00M | 811.00M | 861.00M | 903.00M | 876.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 21533.00M | 20597.02M | 19657.00M | 19236.00M | 18802.00M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | 20.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 495.00M | 496.15M | 243.00M | 399.00M | 211.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 24038.00M | 23967.00M | 24016.00M | 22613.00M | 22613.00M |
| Capital lease obligations | 497.00M | 406.00M | 430.00M | 406.00M | 385.00M |
| Long term debt total | - | - | - | 4305.00M | 4264.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -1865.00000M | -18.00000M | -572.00000M | -1011.00000M | -1001.00000M |
| Change to liabilities | -48.00000M | 60.00M | -21.00000M | 84.00M | 44.00M |
| Total cashflows from investing activities | -1865.00000M | -1198.00000M | -572.00000M | -1011.00000M | -1001.00000M |
| Net borrowings | 208.00M | -63.00000M | 536.00M | 3293.00M | 15.00M |
| Total cash from financing activities | -8.00000M | -123.00000M | 466.00M | 659.00M | -78.00000M |
| Change to operating activities | -192.00000M | 88.00M | -23.00000M | 8.00M | 66.00M |
| Net income | 335.00M | 376.00M | -531.00000M | -656.00000M | -227.00000M |
| Change in cash | -595.00000M | 18.00M | 735.00M | 595.00M | 55.00M |
| Begin period cash flow | 1575.00M | 1557.00M | 822.00M | 227.00M | 172.00M |
| End period cash flow | 980.00M | 1575.00M | 1557.00M | 822.00M | 227.00M |
| Total cash from operating activities | 1217.00M | 1345.00M | 823.00M | 920.00M | 1140.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 1123.00M | 1219.00M | 1626.00M | 1425.00M | 1638.00M |
| Other cashflows from investing activities | - | -18.00000M | -5.00000M | -1.00000M | -1.00000M |
| Dividends paid | -100.00000M | -54.00000M | 54.00M | 54.00M | 54.00M |
| Change to inventory | -217.00000M | -326.00000M | -159.00000M | -108.00000M | -150.00000M |
| Change to account receivables | -164.00000M | -198.00000M | 43.00M | -115.00000M | 53.00M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | 2428.00M | 3.00M | 535.00M | 2720.00M | -78.00000M |
| Change to netincome | 380.00M | 128.00M | -101.00000M | 290.00M | -284.00000M |
| Capital expenditures | 745.00M | 1180.00M | 567.00M | 676.00M | 712.00M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -527.00000M | -314.00000M | -45.00000M | -48.00000M | 80.00M |
| Stock based compensation | 140.00M | 138.00M | 105.00M | 83.00M | -234.00000M |
| Other non cash items | 18.00M | -116.00000M | -228.00000M | -208.00000M | -44.00000M |
| Free cash flow | 472.00M | 165.00M | 256.00M | 244.00M | 428.00M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ALC Alcon AG |
-1.17 1.43% | 80.68 | 39.92 | 28.41 | 4.48 | 2.02 | 4.85 | 31.45 |
| ISRG Intuitive Surgical Inc |
-7.71 1.56% | 485.85 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOY Essilor International SA |
-0.25 0.20% | 122.50 | 35.39 | 24.81 | 3.63 | 2.20 | 4.00 | 16.25 |
| ESLOF EssilorLuxottica Société anonyme |
4.90 2.00% | 249.71 | 35.71 | 25.13 | 3.62 | 2.23 | 4.00 | 16.25 |
| BDX Becton Dickinson and Company |
-1.58 0.95% | 163.88 | 37.72 | 15.92 | 3.25 | 2.49 | 4.08 | 17.10 |
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, grieshaber, MIVS instruments, scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Chemin de Blandonnet 8, Geneva, Switzerland, 1214
| Name | Title | Year Born |
|---|---|---|
| Mr. F. Michael Ball | Exec. Chairman | 1955 |
| Mr. David J. Endicott | CEO & Director | 1965 |
| Mr. Arthur B. Cummings M.D. | Exec. Director | 1962 |
| Mr. Timothy C. Stonesifer | Chief Financial Officer | 1967 |
| Margaret Buckley | Chief Accounting Officer | NA |
| Dr. Franck Leveiller | Sr. VP, Head of Global R&D and Chief Scientific Officer | NA |
| Ms. Sue-Jean Lin | Sr. VP & Chief Information and Transformation Officer | 1969 |
| Mr. Royce R. Bedward | Sr. VP, Gen. Counsel & Corp. Sec. | 1966 |
| Mr. Laurent Attias | Head of Corp. Devel., Strategy, BD&L and M&A | 1968 |
| Ms. Kimberly Martin | Sr. VP & Chief HR Officer | 1975 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.